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Coronary heart disease (CHD) is a set of complex, prevalent,
related conditions that often lead to mortality, including cor-
onary artery disease (CAD) and myocardial infarction (MI).
CHD begins as atherosclerosis, an inﬂammatory disease (1)
that is inﬂuenced by multiple environmental and genetic fac-
tors (2,3). It develops silently into clinical CAD over decades
and may proceed to angina, MI, heart failure, or death.See page 2234Although chromosome 9p21 is a well-established pre-
dictor of CAD (4–7), there is controversy as to whether
it predicts subsequent events after CAD onset (Table 1)
(6–13). Because clinical management approaches differ for
CAD presence and CHD events, further research is necessary
to understand the role of 9p21 variants. To this end, in this
issue of the Journal, Patel et al. (14) performed a systematic
review and meta-analysis encapsulating the experience of
almost 200,000 people for the association of 9p21 (includ-
ing variants rs10757278, rs1333049, rs10757274, rs1333040,
rs2383206, or rs4977574) with CHD.
A strong association of 9p21 with an incident or ﬁrst
CHD event was found among apparently healthy individuals
(nz 168,000 in 16 cohorts) (14), with a hazard ratio that is
consistent with previous reports (4,5). This was in spite of
study differences, including which genetic variant was eval-
uated, the type of plaque, family CHD history, study sample
size, the number of events, and the types of patients. In
contrast, 9p21 did not predict subsequent events (hazard
ratio: 1.01 per risk allele) among patients with diagnosed*Editorials published in the Journal of the American College of Cardiology reﬂect the
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contents of this paper to disclose.CHD (n z 25,000 in 15 cohorts) (14). In the subsequent
events analysis, the proportion of patients with events
(17.6%) was higher than in the ﬁrst-event cohort (9.3%)
despite a shorter follow-up time (3.6 years vs. 11.6 years),
thus it had >99% power to detect the ﬁrst-event hazard ratio
of 1.19 (and >90% power for a hazard ratio of 1.10) (14).
Although a strength of this study is the similar deﬁnitions of
ﬁrst event (i.e., angina, fatal or nonfatal MI, and revasculari-
zation) and subsequent events (i.e., angina, fatal or nonfatal
MI, revascularization, and all-cause mortality) (14), this
produces multiple questions. First, why would a genetic locus
associate with those events at 1 time but not another? Angina
andMI (biological conditions) usually lead tomedical therapy
and interventional treatments, whereas revascularization is a
CHD treatment (not a biological state). As incident events,
their unifying feature is not a shared pathophysiology but the
knowledge of underlying CAD. A ﬁrst event provides infor-
mation about a patient’s coronary status, which arises differ-
entially based on 9p21 genotype. After a patient carries a
CHD diagnosis, though, the goal is the prevention (e.g., via
revascularization) of subsequent angina, recurrentMI, repeat
revascularization, and mortality. Prevention appears to be
achieved similarly well regardless of genotype (6,8–10,14).
Do these ﬁndings help to explain the biological mecha-
nism of 9p21? The strongest association of 9p21 variants is
with CAD presence (which results from atherosclerosis)
(6,7,15). In contrast, 9p21 variants do not associate, per se,
with MI (which arises from plaque instability/rupture and
thrombosis) (6,7). An MI may be the ﬁrst evidence of un-
derlying CAD in some otherwise asymptomatic patients, but
MI can occur in patients with CAD lesions of moderate
stenosis (e.g., <50%) and among those with more sub-
stantial narrowings (16,17). One large, international study
reported that not only 9p21 but also 10 other validated
CHD loci were not associated with MI when compared
with MI-free CAD patients (7). Given the biological
differences between CAD and MI, and because the con-
gruity of study events is CAD status, the study by Patel et al.
(14) supports the involvement of 9p21 in CAD onset and
not in MI precipitation or CHD progression (6,7). (Note:
progression of atherosclerosis is a different, unresolved issue.)
The study by Patel et al. (14) contradicts some reports
(11–13), and the reasons may be varied. One study (included
in themeta-analysis) showed a strong association of 9p21with
subsequent events but only included subjects who were not
initially revascularized; thus, all revascularization events
counted as subsequent outcomes (13). Symptoms that lead to
subsequent coronary revascularization are more likely to occur
in patients with 3-vessel disease (18). Although 3-vessel CAD
(a composite of angiographic information) may not be heri-
table (19), it weakly associates with 9p21 compared with 1- or
2-vessel CAD (13,15). Symptom-based selection for subse-
quent revascularization may have introduced a 9p21-based
bias because of 9p21-associated coronary disease burden.
Finally, other studies (not included in the meta-analysis)
found that 9p21 predicted a higher risk of subsequent
Table 1
Concordance and Discordance of Findings From Papers That Evaluated Associations of the Chromosome 9p21 Locus
With CHD Endpoints
First Author (Ref.#)
Prospective Cohort Study Case vs. Control Comparison
Incident/First
CHD Event
Subsequent
CHD Event
CHD vs.
No CAD
CAD vs.
No CAD
CAD
Burden
MI vs.
No CAD
MI vs.
CAD
McPherson et al. (4) * Signiﬁcant d Signiﬁcant d d d d
Helgadottir et al. (5) d d Signiﬁcant d d Signiﬁcant d
Horne et al. (6) * d Null d Signiﬁcant Null Signiﬁcant Null
Reilly et al. (7) d d d Signiﬁcant d d Null
Hoppmann et al. (8) * d Null d d d d d
Ellis et al. (9) d Null d d d d d
Gong et al. (10) * d Oppositey d d d d d
Buysschaert et al. (11) d Signiﬁcant Signiﬁcant d Null d d
Muehlschlegel et al. (12) d Signiﬁcant d d d d d
Ardissino et al. (13) * d Signiﬁcant d Signiﬁcant Signiﬁcant d d
Fan et al. (15) d d Signiﬁcant Signiﬁcant Signiﬁcantz Signiﬁcant Nullx
Patel et al. (14) Signiﬁcant Null d d d d d
The deﬁnition of coronary heart disease (CHD) in these studies may include but is not limited to: atherosclerosis, coronary artery disease (CAD), angina, myocardial infarction (MI), revascularization, or
mortality. “Signiﬁcant” indicates that the study reported a signiﬁcant association of the 9p21 risk allele with greater risk. “Null” indicates a reported lack of association. “Opposite” refers to a signiﬁcant
association of the 9p21 risk allele with lower risk of CHD. A dash signiﬁes that the study did not test the speciﬁc comparison. *This study was included in the meta-analysis by Patel et al. (14). ySome less-
commonly studied variants (including rs564398) had an allele that was signiﬁcantly associated with greater risk of CHD events, as discussed in the text. zThe strongest association was from a block of 9p21
variants that is less-commonly studied. xSome less-commonly studied variants (including rs564398) had an allele that was signiﬁcantly associated with MI versus MI-free CAD, as discussed in the text.
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2247events, but they tested multiple genetic models whose results
are not signiﬁcant when corrected for multiple comparisons
(11,12).
Interestingly, 2 studies evaluated an infrequently studied
block of 9p21 variants (including rs564398) that associated
weakly with less 3-vessel disease (15) (i.e., more 1- or 2-vessel
disease) and signiﬁcantly with greater risk of MI (15) or MI,
stroke, and death (10). (Note: neither study’s endpoint deﬁ-
nition included revascularization.) Although these 9p21
variants may function in platelet reactivity (15), a simpler
explanation is that patients with the other allele (e.g., the
rs564398 allele associated with 3-vessel disease) were more
likely to undergo revascularization due to symptoms and,
consequently, were better protected from subsequent MI and
other CHD events. However, this is speculative. Further
research is needed on rs564398 and related variants.
That chromosome 9p21 variants do not associate with sub-
sequent events (14) in no way detracts from the landmark
discovery that they predictCADonset (4,5). The identiﬁcation
of the 9p21 CAD locus is an important advance in the un-
derstanding of human health that pre-genetic science was un-
able to reveal. Prior to 2007, 9p21 variants were not considered
cardiac risk factors, whereas hypertension, hyperlipidemia,
smoking, and others were known (2). This locus is enlightening
our understanding of CAD pathophysiology by opening pre-
viously invisible doors that may lead to a myriad of new
knowledge, CHD biomarkers, treatments, and care pathways.
The meta-analysis by Patel et al. (14) suggests that in-
dividuals with the 9p21 risk allele are at increased risk for an
incident CHD event, but not subsequent events (14).
Although 9p21 genetic testing in the clinic has not and may
not become a reality, the insights arising from 9p21 in-
vestigations should lead to new methods in the future for the
prevention and diagnosis of a ﬁrst CHD event.Reprint requests and correspondence: Dr. Benjamin D. Horne,
Intermountain Heart Institute, Intermountain Medical Center,
5121 South Cottonwood Street, Salt Lake City, Utah 84107.
E-mail: benjamin.horne@imail.org.
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